What started as glucose-lowering agents has turned into a major player in obesity management, cardiometabolic risk reduction, and now, possibly, cancer outcomes
Short-acting GLP-1RAs, such as exenatide and lixisenatide, have a half-life of 24 h, requiring daily administration once or twice a day
Sequential Introduction Strategy The most widely recommended approach when combining these peptides is sequential introduction rather than starting both simultaneously
Bera, K., Kiepas, A., Godet, I., Li, Y., Mehta, P., Ifemembi, B., et al
320 , R697R703 (2021)
Common side effects are minimal and localizedmild soreness, redness, or bruising at the injection site typically resolve within hours to days